Drugs / ARS-1
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04930900 | Aug 2021 → Mar 2022 | respiratory tract infectious disorder | ARS Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05496465 | Jul 2022 → Feb 2024 | urticaria | ARS Pharmaceuticals, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05363670 Comparator | Jul 2022 → Feb 2024 | asthma | ARS Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARS-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04930900 ↗ |
| Route | Intranasal | “1 mg ARS-1 IN” NCT05496465 ↗ |